MedTrace Logo

Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4

NCT04382339 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2020-05-11

No results posted yet for this study

Summary

This study aims to assess the efficacy and safety of sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 participants

Conditions

  • Hepatitis C Virus Infection

Interventions

DRUG

SOF/RBV/PegINFα-2

SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Mohammed Abdel-Gabbar, Ass. Prof · Biochemistry Dep., Faculty of Science, Beni-Suef University, P.O. Box 52621

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-11-30
Completion
2015-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04382339 on ClinicalTrials.gov